Table 2.
Time course of immunosuppressive agents in cardiac transplant recipients receiving low-dose EVL (LD) or high-dose EVL (RD).
| Parameter | T 0 | T 1 | T 3 | T 6 | T 9 | T 12 | P value |
|---|---|---|---|---|---|---|---|
| Everolimus (μg/L) | |||||||
| LD group | — | 4.34 ± 2.63 | 3.59 ± 1.44*** | 3.66 ± 2.06*** | 3.34 ± 1.22*** | 3.10 ± 1.02*** | 0.139 |
| RD group | — | 5.22 ± 2.63 | 5.76 ± 2.53 | 6.24 ± 2.49 | 5.31 ± 1.86 | 5.28 ± 2.01 | 0.096 |
| CSA (μg/L) | |||||||
| LD group | 102.0 ± 31.5 | 70.1 ± 38.8 | 51.0 ± 15.6 | 51.4 ± 19.5 | 47.8 ± 18.8 | 43.1 ± 13.6 | <0.001 |
| RD group | 91.3 ± 26.1 | 60.3 ± 30.0 | 48.2 ± 27.8 | 50.6 ± 27.5 | 48.8 ± 22.4 | 43.1 ± 19.7 | <0.001 |
| TAC (μg/L) | |||||||
| LD group | 9.10 ± 2.10 | 6.49 ± 2.91 | 5.26 ± 1.42 | 5.74 ± 2.36 | 4.48 ± 0.94 | 4.75 ± 1.10 | <0.001 |
| RD group | 8.88 ± 2.14 | 6.71 ± 2.69 | 4.89 ± 1.42 | 4.68 ± 1.28 | 5.20 ± 2.18 | 5.67 ± 1.88 | <0.001 |
***Significant different from RD group at the same time point.